Heparin (Lithium) for Interference Testing

Heparin (Lithium) for Interference Testing is a biotechnology-grade reagent formulated to simulate anticoagulant interference in clinical assay validation workflows. Supplied as a highly pure powder with an activity of >150 U/mg and a total of 2500 units, this ready-to-use lithium salt of heparin enables researchers to spike specimens and evaluate assay robustness, specificity, and analytical accuracy. It is particularly valuable in validating immunoassays, coagulation tests, and biochemical platforms where lithium heparin may impact analyte detection or assay kinetics.

Researchers in clinical chemistry, hematology, and diagnostic assay development rely on interference testing to meet CLSI EP07 guidelines and ensure reliable performance across diverse sample types. This reagent is manufactured using ultrapure water and filtered through 0.22 µm membranes to ensure minimal background interference and maximum reproducibility. Stored at room temperature, it integrates seamlessly into manual and automated workflows. Whether you're developing a lithium heparin-sensitive assay or troubleshooting unexpected signal variation, this reagent provides a precise and reproducible solution for interference evaluation.

Key benefits:

• Highly pure lithium heparin powder (>150 U/mg) for interference simulation

• Supports EP07-compliant assay validation and robustness testing

• Ready-to-use format for direct specimen spiking

• Filtered through 0.22 µm membranes using ultrapure water

• Stable at room temperature for convenient storage and use

Products are for in vitro research use only (RUO).

References

• 1: Bolten SN, Rinas U, Scheper T. Heparin: role in protein purification and
  substitution with animal-component free material. Appl Microbiol Biotechnol.
  2018 Oct;102(20):8647-8660.
• 2: Cassinelli G, Naggi A. Old and new applications of non-anticoagulant heparin.
  Int J Cardiol. 2016 Jun;212 Suppl 1:S14-21.
• 3: Liu X, St Ange K, Wang X, Lin L, Zhang F, Chi L, Linhardt RJ. Parent heparin
  and daughter LMW heparin correlation analysis using LC-MS and NMR. Anal Chim
  Acta. 2017 Apr 8;961:91-99.
• 4: Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation:
  potential therapeutic applications beyond anticoagulation. Adv Pharmacol.
  1999;46:151-208.
• 5: Masuko S, Linhardt RJ. Chemoenzymatic synthesis of the next generation of
  ultralow MW heparin therapeutics. Future Med Chem. 2012 Mar;4(3):289-96.
• 6: Bertini S, Fareed J, Madaschi L, Risi G, Torri G, Naggi A. Characterization
  of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential.
  Clin Appl Thromb Hemost. 2017 Oct;23(7):725-734.
• 7: Walenga JM, Lyman GH. Evolution of heparin anticoagulants to ultra-low-
  molecular-weight heparins: a review of pharmacologic and clinical differences
  and applications in patients with cancer. Crit Rev Oncol Hematol. 2013
  Oct;88(1):1-18.
• 8: Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA. Unfractionated
  heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of
  actions, pharmacology, and clinical use. Hematol Oncol Clin North Am. 2005
  Feb;19(1):1-51, v.
• 9: Ouyang Y, Zeng Y, Yi L, Tang H, Li D, Linhardt RJ, Zhang Z. Qualitative and
  quantitative analysis of heparin and low molecular weight heparins using size
  exclusion chromatography with multiple angle laser scattering/refractive index
  and inductively coupled plasma/mass spectrometry detectors. J Chromatogr A. 2017
  Nov 3;1522:56-61.
• 10: Hull RD, Pineo GF, Stein P. Heparin and low-molecular-weight heparin therapy
  for venous thromboembolism. The twilight of anticoagulant monitoring. Int
  Angiol. 1998 Dec;17(4):213-24.
• 11: Xiao Z, Tappen BR, Ly M, Zhao W, Canova LP, Guan H, Linhardt RJ. Heparin
  mapping using heparin lyases and the generation of a novel low molecular weight
  heparin. J Med Chem. 2011 Jan 27;54(2):603-10.
• 12: Padma V, Fisher M, Moonis M. Role of heparin and low-molecular-weight
  heparins in the management of acute ischemic stroke. Expert Rev Cardiovasc Ther.
  2006 May;4(3):405-15.
• 13: Li G, Yang B, Li L, Zhang F, Xue C, Linhardt RJ. Analysis of 3-O-sulfo
  group-containing heparin tetrasaccharides in heparin by liquid chromatography-
  mass spectrometry. Anal Biochem. 2014 Jun 15;455:3-9.
• 14: Kalathottukaren MT, Abbina S, Yu K, Shenoi RA, Creagh AL, Haynes C,
  Kizhakkedathu JN. A Polymer Therapeutic Having Universal Heparin Reversal
  Activity: Molecular Design and Functional Mechanism. Biomacromolecules. 2017 Oct
  9;18(10):3343-3358.

All Interference Products Brochure